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Abstract
Background: Hunter syndrome (mucopolysaccharidosis type II, MPS II) is a rare disease inherited in an X-linked autosomal
recessive pattern. It is the prevailing form of the mucopolysaccharidoses in China. Here we investigated mutations of IDS
(iduronate 2-sulfatase) gene in 38 unrelated Chinese patients, one of which is a female.
Methods: Peripheral leucocytes were collected from the patients and the IDS gene was amplified to looking for the
variations. For a female patient, the X chromosome status was analyzed by androgen receptor X-inactivation assay and the
mutation impact on RNA level was further performed by reverse transcription polymerase chain reaction.
Results: We discovered that point mutations constituted the major form while mutations in codon p.R468 defined the
largest number of patients in our cohort. Consistent with data from other ethnic groups, exons 9 and 3 had comparatively
more mutations, while exon 2 had quite a few mutations unique to Chinese patients. Of the 30 different mutations
identified, only 9 were novel: one was a premature termination mutation, i.e., c.196C.T (p.Gln66X); three were missense
mutations, i.e., c.200T.C (p.Leu67Pro), c.215T.C (p.Leu72Pro), c.389C.T (p.Thr130Ile); one was a small deletion, i.e.,
c.1104_1122del19 (p.Ser369ArgfsX16); and one was a deletion that spanned both exons 8 and 9 deletion leading to gross
structural changes in the IDS gene. In addition, a synonymous mutation c.879G.A (p.Gln293Gln) was identified in a female
Hunter disease patient, which resulted in loss of the original splicing site, activated a cryptic splicing site upstream, leading
to a 28 bp deletion and a premature termination at p. Tyr285GlufsX47. Together with concurrent skewed X-inactivation this
was believed to facilitate the development of Hunter disease in this girl.
Conclusions: In conclusion, the molecular analysis of IDS gene in Chinese patients confirmed the Hunter disease diagnosis
and expanded the mutation and clinical spectrum of this devastating disorder.
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Introduction
Hunter syndrome (MPS II; OMIM 309900), is caused by
deficiency of the lysosomal enzyme iduronate 2-sulfatase (IDS, EC
3.1.6.13) which functions in the catabolism of two glycosamino-
glycans, dermatan sulphate and heparan sulphate. A deficiency of
IDS leads to dermatan sulphate and heparin sulphate accumula-
tion mainly in connective tissue, liver, spleen, and brain, with
excretion in the urine, even during fetal development. After birth,
disease symptoms present at various times reflecting a wide disease
spectrum, from a mild form without cognitive involvement to a
severe form with early onset, mental retardation, rapid progression
and death in the first or second decade of life.
The IDS gene located on chromosome Xq28 consists of 9 exons
encoding a 550-amino acid IDSprotein. The presence of severaltranscripts
in normal humans reflects a complex system of intron splicing and strongly
suggests that the IDS gene is susceptible to splicing mutations. About 80 kb
downstream of thetranscribed IDSgene, there is an IDS pseudogene, called
IDS2. It is homologous in exons 2 and 3, and introns 2, 3, 7 of transcribed
IDS [1], where exon 3 is 100% identical and the other sequences are 96%
identical. The presence of a pseudogene likely renders the IDS gene more
prone to recombination [2]. To date, more than 350 mutations have been
identified in the IDS gene (www.hgmd.org), with exonic point mutations
comprising half the mutations, followed sequentially by small deletions,
altered splicing, gross deletions, small insertions, complex rearrangements,
small indels, and gross insertions/duplications,.
As suggested previously [3] the IDS genotype correlates in
general with the clinical phenotype. Usually, gross structural
changes including large deletions and gene-pseudogene recombi-
nations are associated with severe phenotypes, while small gene
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siblings from the same family may show completely different
clinical courses [4], it is highly likely that in addition to the primary
action of IDS gene, other factors modify its effects on the clinical
presentation of Hunter syndrome.
MPS II is the predominant form of mucopolysaccharidoses
among Japanese, Koreans, Jews [5], and Chinese [6,7], which is
different from other ethnic associations. For example, MPS III
(where there are 4 distinct genetic entities) has a higher incidence
than other forms of MPS in Western Australians [8], Germans [9],
and Netherlanders [10], while Brazilians have a high incidence of
MPS VI [11].
Herein we report the IDS mutation spectrum among the largest
collection of Chinese patients with Hunter syndrome and compare
it with those in other populations. Although this disorder affects
primarily males, nearly a dozen female patients have been
documented so far [12,13] where most female patients arise from
skewed X-inactivation. Here the underlying molecular mechanism
for the disease in a Chinese female was also investigated.
Materials and Methods
Patients
Informed consents from the parents were obtained as approved
by the local Institutional Review Ethics Board. A total of 38
unrelated patients with Hunter syndrome, one of which was
female, were registered from our genetic metabolism clinic. These
patients initially suspected of having mucopolysaccharidosis due to
growth retardation, short stature, or bone dysmorphology
examined by x-ray were confirmed by urine excretion of dermatin
sulphate following glycosaminoglycan electrophoresis, and by low
IDS activity in leukocytes from peripheral blood. A second
sulphatase, i.e. arylsulfatase A, was measured to preclude the
multiple sulphatase deficiency. Clinically patients were classified as
severe if they had mental retardation and as mild based on normal
mental status, as reported by Froissart et al [14]. Measurement of
IDS activity in leukocytes was carried out in accordance with
Voznyi et al [15]. The gender identity of the female patient with
Hunter syndrome was confirmed by negative SRY (sex determining
region Y) gene amplification.
IDS Genomic DNA analysis
Genomic DNA was extracted from peripheral blood using the
DNA isolation kit RelaxGene blood DNA DP319-01 (Tiangen,
China) according to the manufacturer’s protocol. All exons and
their flanking regions of the IDS gene were amplified with primers
designed by Primer3 except for exon 3, as reported previously
[16]. Amplification reactions were performed in a total volume of
25 mL in the presence of 2.5 mLo f1 0 6 PCR buffer (Qiagen),
0.2 mmol/L of each dNTP, 0.4 Umol/L of each primers and
0.5 U of tag DNA polymerase (Qiagen), and 200 ng DNA. For
amplification of Exon 1, 3, 5, 6, 7, 8 and 9, the samples were
predenatured by heating to 95uC for 5 min, followed by 35 cycles
consisting of denaturation at 94uC for 40 sec, annealing at 61uC
for 40 sec, and extension at 72uC for 1 min, and subsequently for
10 min at 72uC. For amplification of exons 2 and 4, the conditions
were the same as for other exons, except that the annealing
temperatures were 60uC and 67.5uC, respectively. Amplicons were
purified and sequenced directionally to search for mutations and/
or variations using an ABI PRISM Dye Terminator Cycle
Sequencing Kit, and an ABI 3700 automated fluorescent
sequencer (PE Applied Biosystems, Foster City, CA).
The method, reported by Lualdi and colleagues [17], was used
to search for gene-pseudogene recombinations in patients where
no mutations were identified by exon sequencing, and in patients
where any of the exons failed to be amplified. The first set of
primers was also used to evaluate whether the pseudogene was
involved in the large deletion of IDS gene. The negative
amplification indicated the large deletion included both the IDS
gene and the pseudogene.
Androgen receptor X-inactivation assay
This assay was used to analyze the status of X chromosome
inactivation in the female Hunter patient, which was performed as
described [18]. The forward primer was FAM-labeled. PCRs were
performed as documented with products run on an ABI Prism
3730 DNA Analyzer (Applied Biosystems) and analyzed using the
Peak Scanner Version 1.0 software (Applied Biosystems).
IDS cDNA analysis
Since a synonymous variation was identified in the female
Hunter syndrome patient, the RNA of her and that from her sister
was further analyzed to check the impact on RNA level. Total
cellular RNA was isolated from peripheral blood using PAXgen-
e
TM blood RNA kit (Qiagen) with the protocol provided by the
manufacturer and stored in the PAXgene
TM blood RNA tube.
RNA was then reverse transcribed using PrimeScript
TMRT
reagent kit (TaKaRa, Japan), with a reaction volume 10 mL
containing 200 ng of total RNA, 1 mL of RT Enzyme Mix I, 2 mL
of 56 Buffer, and 0.5 mL of Oligo dT Primer. The tube was
incubated at 37uC for 15 min, then heated to 85uC for 5 sec to
denature the PrimeScriptH RTase. Primers were designed to cover
the mutation found in the female patient (table 1), which was
applied with 3 mL of reverse-transcribed product to amplify this
1242-bp sequence. The amplicons were first run on the 1%
agarose gel to check whether the apparent molecular weights of
Table 1. Primers used for amplifying exons and cDNA.
Name Primer sequence ((59R39)
Annealing
T(6C)
Length
(bp)
e1F CTGTGTTGCGCAGTCTTCAT 61 676
e1R ATGCAGGAAAGGACAGATGG
e2F CCATCTGTCCTTTCCTGCAT 60 561
e2R TAACAAGATGTCCCGCACAA
e3F GCTGTGGCGATGCTTACCTCTG 61 250
e3R AAGAGAACCCAGACTCTGGACA
e4F GGCTTAGGGACCAGGAAGTC 67.5 508
e4R AACAAGTAGCACCCACCAGC
e5F CCTGCCTGGAAAACAAGAAA 61 552
e5R GGCCTTGACCTCTAAATCCC
e6F ACGTGGGGAATGCTAGTGAG 61 514
e6R GTTGGGAGAGTCCTGATCCA
e7F GCTGTGACTCTGTGGGTGAA 61 627
e7R CCAGGTTAAAAATGGGGGTT
e8F CAGCCTGTCAAGAATGAGCA 61 623
e8R ACCCCCAAAGCCTATGATTC
e9F CATATGGAGCCCAGACAGGT 61 610
e9R GGAAGGGAGCACATCACATT
p-cDNA-F GCGGCGGCTGCTAACTG 58 1242
p-cDNA-R CAACTGTGAGGCGGAATCAA
doi:10.1371/journal.pone.0022951.t001
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the IDS RNA in the patient. The amplicons were then sequenced
bidirectionally.
Results
Mutation spectrum of IDS in Chinese patients
Among these 38 unrelated Chinese patients with Hunter
syndrome, 37 of them have been identified with IDS gene
variations. All the variations were considered to be causative for
Hunter disease, since they were not found in 100 alleles from
normal people. No second variation existed in the same patient
except in one male patient where two variations identified (see
below). In one patient, no mutation was found after sequencing all
coding exons and was found free of gene-pseudogene recombina-
tion.
A total of 30 different mutations, including 9 novel mutations
and 21 previously reported mutations (Table 2), were identified.
These were categorized as exonic point mutations, small deletions,
intronic mutations, small insertions, gross deletions, and recom-
binations according their impact at the genomic level. While
mutations were found in all exons they were concentrated in exon
9 (21%; 8/38), exon 2 (11%; 4/38) and exon 3 (11%; 4/38).
Exonic point mutations were predominant and comprised 58%
(22/38) of all alleles. One synonymous mutation c.1122C.T
(p.Gly374Gly), common in Caucasians [19,20] that lead to a splice
mutation with deletion of 20 amino acids of IDS protein [21], was
included in this category for the sake of simplicity. Also included
was a new same sense mutation c.879G.A (p.Gln293Gln)
identified in a female with Hunter syndrome, proved to result in
a splice mutation in our report. The second largest group of
mutations involved large structural changes, including gross
deletions and gene-pseudogene recombinations, comprised 29%
(11/38) of the total.
Unlike most mutations that were unique or individualized, the
codon 468 position could be considered a ‘‘hot’’ spot as 5 patients
Table 2. Summary of mutations in a Chinese cohort of Hunter syndrome and their corresponding phenotypes.
Category Mutation Consequence Occurrence Position Phenotype Status
Exonic point mutation c.1402C.T p.Arg468Trp 3 ex.9 severe reported
c.1327C.T p.Arg443X 2 ex.9 mild reported
c.1403 G.A p.Arg468Gln 1 ex.9 severe reported
c.[1267C.T+1402C.T] p.[Pro423Ser+Arg46Trp] 1 ex.9 severe novel
c.1505G.A p.Trp502X 1 ex.9 severe reported
c.196C.T p.Gln66X 1 ex.2 severe novel
c.200T.C p.Leu67Pro 1 ex.2 severe novel
c.215T.C p.Leu72Pro 1 ex.2 severe novel
c.238C.T p.Gln80X 1 ex.2 severe reported
c.263G.A p.Arg88His 2 ex.3 severe reported
c.323A.C p.Tyr108Ser 1 ex.3 mild reported
c.389C.T p.Thr130Ile 1 ex.3 mild novel
c.941T.C p.Leu314Pro 1 ex.7 mild reported
c.998 C.T p.Ser333Leu 1 ex.7 severe reported
c.514C.T p.Arg172X 1 ex.5 mild reported
c.879G.A p.Gln293Gln
(p.Tyr285GlufsX47)
1 ex.6 mild novel
c.1122C.T p.Gly374Gly
(20 amino acid deletion)
1 ex.8 severe reported
c.95C.A p.Ser32X 1 ex.1 severe reported
Small deletion c.1104_1122del19 p.Ser369ArgfsX16 1 ex.8 severe novel
c.596_599del4 p.Lys199AspfsX14 1 ex.5 severe reported
Small insertion c.161–162insA p.Tyr54X 1 ex.2 severe novel
Intronic mutation c.880-8A.G 1 intron 6 mild reported
Gross deletion EX8_9del 2 ex.8 and ex.9 severe novel
EX8del 2 ex.8 severe reported
EX_9del
(pseudogene intact)
1 severe reported
EX1_9del
(including pseudogene)
1 severe reported
EX4del 1 ex.4 severe reported
Recombination type A 2 severe reported
type B 1 severe reported
type C 1 severe reported
doi:10.1371/journal.pone.0022951.t002
IDS Mutations in Chinese Hunter Syndrome Patients
PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e22951Figure 1. Homology alignment of amino acid sequences among IDS, N-acetylgalactosamine-6S sulfatase, arylsulfatase A, and
arylsulfatase B. Residues identical in at least two of four sulfatases were shaded by blue, with more identity, the color used deeper. GALNS, ASA,
and ASB were the short forms of N-acetylgalactosamine-6S sulfatase, arylsulfatase A, and arylsulfatase B, respectively.
doi:10.1371/journal.pone.0022951.g001
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Two other previously reported mutations, p.Arg443X and
p.Arg88His, each occurred twice.
Novel Mutations
Of the 22 exonic point mutations identified, most had been
reported while in 6 patients with novel mutations, five of them
were single changes, while one patient had two changes. The five
single mutations were: c.196C.T (p.Gln66X), c.200T.C
(p.Leu67Pro), c.215T.C (p.Leu72Pro), c.389C.T (p.Thr130Ile)
and c.879G.A (p.Gln293Gln). In one patient and his mother, a
novel variation c.1267C.T (p.Pro423Ser) was found to coexist
with a previously reported mutations, c.1402C.T (p.Arg468Trp).
The p.Leu67Pro, p.Leu72Pro, and p.Thr130Ile, all located near
the active centre C84 of IDS, appear conserved, being identical
in three of the four human arylsulfatases, including N-acetylga-
lactosamine-6S sulfatase, arylsulfatase A, and arylsulfatase
B. However, Proline 423 is less conserved, being identical in
two of the four arylsulfatases (Figure 1). Neither p.Leu67Pro
nor p.Leu72Pro was likely to activate new cryptic splicing sites
as judged from the Maxent program (http://genes.mit.edu/
burgelab/maxent/Xmaxentscan_scoreseq.html).
Although only 3 individuals (8%, 3/38) had small deletion/
insertion mutations, two of them were novel. The small deletion
c.1104_1122del19 in exon 8 led to an amino acid change at codon
369 and a premature termination codon 16 amino acids later. The
small insertion c.161–162insA generated an early premature stop
codon at residue 54.
The gross structural changes seen have been identified in other
ethnic groups, except for the deletion of both exon 8 and 9 of IDS
gene which has not been documented previously. This mutation
occurred in two patients in our cohort. With the deletion of these
two exons, the cDNA was presumed to encode a peptide
containing about 60% of the entire IDS protein. Whether the
deletion extended to IDS pseudogene and gene W was not further
investigated in these two patients. If a residual gene W were to
exist, a fusion protein between partial IDS and gene W would be
synthesized as reported [22].
The molecular analysis of the female patient
The variation c.879G.A, located in the last nucleotide of exon
6, was identified in the female Hunter patient. Her mother and a
female sibling were carriers of this mutation. The father did not
carry any mutation at this site.
Since only one mutation was identified in the female patient,
and the gender authenticity was proved by negative SRY
amplification, we investigated the methylation status of Androgen
receptor to determine if skewed X-inactivation could be the basis
for her disease. Her mother showed a 60:40 X-inactivation pattern
(Figure 2), which was a random form of this process and consistent
with her carrier status. The pattern of X- inactivation in the female
patient was .95:5, which documents a skewed X-inactivation. She
showed the same signal peak after HpaII digestion as her father
indicating she received the androgen receptor allele from her
father, i.e, the mutated IDS gene from the mother was selected for
expression.
ESE (exonic splicing enhancer) finder (http://rulai.cshl.edu/
cgi-bin/tools/ESE3/esefinder.cgi) predicted that c.879G.A
would disrupt the ESE site at end of exon 6 and lose the original
59 splice donor site. To prove this prediction, RNA was isolated
and amplified. We found the IDS RNA level (panel A of Figure 3)
was greatly reduced in the female patients, as well as in her
mutation-carrier sibling. Although no apparent difference of
amplicons was shown on the agarose gel, their sequencing
revealed the distinction between a patient and a mutation carrier.
Since the mutation was located in the latter half of this amplicon,
forward sequencing could not show the changed nucleotides (panel
B of Figure 3 displays the reverse sequencing). It is notable that
both the patient and the carrier had a major transcript, despite the
existence of minor transcripts. By comparing the major transcripts
with IDS cDNA reference (NM_000202.5), we could see that the
carrier had a normal one, while the patient’s is 28 bp shorter,
which demonstrated an upstream alternative cryptic splice-site
mutation was activated. These sequencing data were concordant
with the respective enzymatic activities in their peripheral
leucocytes, 1 and 8.71 nmol/4 h/mg (normal range: 16.4 to 83.2).
Discussion
Mutation category
The mutation spectrum in our series of unrelated 38 patients
had the following features: i) exonic point mutations comprised the
majority of all mutations; ii) the incidence of large structural
changes was high, comparable to those found in France [23],
Australia [24], Japan [25] ; iii) the small deletion/insertion
mutation was quite rare (only 3 individuals belonged to this
category) compared with Caucasian [19,20,26], and South
Korean populations [27]; iv) the mutations involving introns were
also scarce. Only one reported mutation c.880-8A.G had been
identified in our group in contrast to data from a Portuguese study,
where a high frequency (6/16) of intronic splicing mutation was
identified [19].
The most frequent mutation and mutation distribution
Arginine 468 is a recurrent point mutation in nearly all ethnic
groups. In a group of 43 Japanese with Hunter syndrome, 5 had
Figure 2. Androgen receptor X- inactivation assay in the female
patient with Hunter syndrome. An X-inactivation pattern .95:5
was noted in the female patient (P130), while her mother (P130M)
showed an pattern 60:40. After digestion by HpaII, the female patient
showed the same signal as her father (P130F) indicating that the
androgen receptor gene on the allele from her father was methylated
and preserved.
doi:10.1371/journal.pone.0022951.g002
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other two had p.Arg468Trp and p.Arg468Leu, respectively [25].
In a report of United Kingdom patients, four individuals carried
the p.Arg468Gln mutation [28]. The mutation p.Arg468Gln was
also exclusive in 5 out of 40 Italian patients [29] whereas the
p.Arg468Trp and p.Arg468Gln mutations occurred with equal
frequency and comprised nearly half (6/14) of all mutations in
Taiwanese [30].
In our group, R468 was mutated in 5 individuals, of whom
three were p.Arg468Trp, one was p.Arg468Gln, and one showed
the combination of p.Arg468Trp with p.Pro423Ser. The R468
mutation had been shown to coexist with p.Arg101Cys, a rare
polymorphism [31]. The p.Pro423Ser has never previously been
found in Hunter disease. Since this patient had a classical severe
Hunter disease, and p.Arg468Trp was already known to be
associated with a severe type by itself, p.Pro423Ser was predicted
to make a minor contribution to the phenotype. It was likely that
p.Pro423Ser was also a rare polymorphism and p.Arg468Trp was
the pathogenic mutation for this patient. The p.Arg468Trp has
comparatively higher occurrence in Chinese than in other
populations.
The synonymous mutation c.1122C.T (p.Gly374Gly) leading
to a 20 amino acid deletion of the IDS protein was the most
common mutation in Spanish patients [20], and has a higher
frequency in other Caucasian populations [24,32], appeared
randomly in our collection.
The IDS mutations widely distributed throughout the whole 9
exons were frequently located in exon 9, exon 8, and exon 3, as
documented in Caucasians [21,25] and Japanese patients [25].
Our data were largely in agreement except that p.Gln66X,
p.Leu67Pro, and p.Leu72Pro were located in exon 2, which is
distinctive and suggests exon 2 may be a unique ‘‘hot spot’’ in
Chinese Hunter patients.
Genotype-phenotype correlation
Consistent with previous reports, gross gene structure alterations
were associated with a severe clinical phenotype, except for one
patient with exon 4 deletion, who had an attenuated form, while
Vafiadaki and co-workers [28] described a severe form with the
same deletion.
Our patients with nucleotide 468 changes always had a severe
phenotype, as for the Japanese [25], United kingdom [28], and
Taiwanese groups [30], while in a few reports it was associated
with mild clinical phenotypes [33].
As for the novel mutations, the nonsense mutation (p.Gln66X)
would lead to deletion of about 90% of IDS amino acid sequence
[34] and could explain a severe clinical presentation. Both
p.Leu67Pro and p.Leu72Pro are conserved among human
Figure 3. The molecular analysis at RNA level of IDS gene in a girl. Compared with normal female control, IDS gene presented remarkably low
RNA expression in both the patient (P130) and her female sibling (P130S) (Panel A). The RNA sequencing revealed the patient (P130) had an abnormal
sequence as the major transcript while her phenotypically normal sister had a normal sequence as the major transcript (Panel B).
doi:10.1371/journal.pone.0022951.g003
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helix and b-sheet, respectively. Substitution by Proline confers
exceptional conformation rigidity, would likely interrupt the
secondary structure of IDS protein, and decrease the IDS activity
significantly. Tyrosine at codon 130 is also conserved and
conversion to the hydrophobic isoleucine would also lower the
IDS activity.
RNA splicing in female Hunter patient
Our female patient with Hunter syndrome inherited a single
point synonymous IDS gene mutation, leading to abnormal
mRNA splicing, from her mutation-carrying mother. Simulta-
neously she had skewed X-inactivaton of the paternal allele
resulting in the maternal allele harboring the mutation being
transcribed. This combination accounts for most of the female
patients with an X-linked autosomal recessive disorder [18,35].
She was expected to have expressed only the mutant cDNA. The
existence of some minor transcripts besides the major mutated one
support complexities in the regulation system of IDS gene
transcription, which require further investigation, as Lualdi et al
reported [36]. Beside the major normal transcript in her carrier
sister, there was some small amount of abnormal transcripts. The
larger parts of the abnormal transcripts were possibly rapid
degraded after synthesis by nonsense-mediated mRNA decay since
c.879G.A (p.Gln293Gln) introduced a premature termination
codon at 47 amino acids later after the first amino acid change.
Conclusion
Herein we report mutations in a large group of mainland
Chinese patients with Hunter syndrome, who share similarities to
those of other populations, while manifesting population unique
features. The novel mutation expands the IDS gene mutation
spectrum and contributes the knowledge about the IDS protein
structure.
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